These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26524267)

  • 1. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.
    Haji S; Kiyasu J; Choi I; Suehiro Y; Toyoda K; Tsuda M; Takamatsu A; Nakashima Y; Miyoshi H; Shiratsuchi M; Yamasaki S; Uike N; Abe Y
    Bone Marrow Transplant; 2016 Mar; 51(3):432-4. PubMed ID: 26524267
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
    Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
    Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy].
    Suwabe T; Shibasaki Y; Kaihatsu A; Katagiri T; Miyakoshi S; Fuse K; Kobayashi H; Ushiki T; Moriyama M; Takizawa J; Narita M; Sone H; Masuko M
    Rinsho Ketsueki; 2017; 58(1):32-36. PubMed ID: 28190863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation.
    Ito Y; Miyamoto T; Chong Y; Aoki T; Kato K; Akashi K; Kamimura T
    Bone Marrow Transplant; 2013 Jul; 48(7):998-9. PubMed ID: 23292237
    [No Abstract]   [Full Text] [Related]  

  • 5. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
    Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
    Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
    [No Abstract]   [Full Text] [Related]  

  • 6. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
    Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR4 and its ligands: from bench to bedside.
    Yoshie O; Matsushima K
    Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.
    Ishitsuka K; Murahashi M; Katsuya H; Mogi A; Masaki M; Kawai C; Goto T; Ishizu M; Ikari Y; Takamatsu Y; Ishibashi H; Nimura S; Takeshita M; Tamura K
    Int J Hematol; 2015 Oct; 102(4):493-7. PubMed ID: 25995001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
    Shimazu Y; Nohgawa M
    Leuk Lymphoma; 2019 Dec; 60(12):3092-3093. PubMed ID: 31104532
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab.
    Furukawa M; Ikeda K; Ohkawara H; Saito S; Takahashi H; Ueda K; Matsumoto H; Hashimoto Y; Ohto H; Ogawa K; Takeishi Y
    Int J Hematol; 2015 Oct; 102(4):498-505. PubMed ID: 25975265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.
    Hosoi H; Mushino T; Nishikawa A; Hashimoto H; Murata S; Hatanaka K; Tamura S; Hanaoka N; Shimizu N; Sonoki T
    Int J Hematol; 2018 Jun; 107(6):717-719. PubMed ID: 29671245
    [No Abstract]   [Full Text] [Related]  

  • 14. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.
    Ishida T; Jo T; Takemoto S; Suzushima H; Suehiro Y; Choi I; Yoshimitsu M; Saburi Y; Nosaka K; Utsunomiya A; Kobayashi Y; Yamamoto K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Imada K; Kato K; Moriuchi Y; Yoshimura K; Takahashi T; Tobinai K; Ueda R
    Br J Haematol; 2019 Feb; 184(3):479-483. PubMed ID: 29411857
    [No Abstract]   [Full Text] [Related]  

  • 16. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
    Iida S; Ishida T; Ueda R
    Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
    Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
    Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
    [No Abstract]   [Full Text] [Related]  

  • 19. [Adult T cell leukemia-lymphoma with allo-HSCT after treatment for pulmonary involvement with Mogamulizumab].
    Kawashima I; Sueki Y; Yamamoto T; Nozaki Y; Nakajima K; Mitsumori T; Kirito K
    Rinsho Ketsueki; 2015 Feb; 56(2):210-5. PubMed ID: 25765802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mogamulizumab for the treatment of T-cell lymphoma.
    Makita S; Tobinai K
    Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.